RUNX1 and acute myeloid leukemia: Here we show that targeting RUNX1/ETO by a chemically modified siRNA encapsulated into LNPs interferes with leukaemic propagation both in tissue culture and in vivo suggesting this approach as a therapeutic option for t(8;21) AML patients.